European equities traded in the US as American depositary receipts were edging lower late Friday morning, declining 0.17% to 1,514.13 on the S&P Europe Select ADR Index, which is up 1.8% for the week.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and internet browser company Opera (OPRA), which rose 2.5% and 2.2% respectively. They were followed by telecommunications company Nokia (NOK) and pharmaceutical company Novo Nordisk (NVO), which were up 2.1% and 1.7% respectively.
The decliners from continental Europe were led by accommodations booking site trivago (TRVG) and biopharmaceutical company argenx (ARGX), which fell 0.9% and 0.7% respectively. They were followed by internet browser company Criteo (CRTO) and software firm SAP (SAP), which were down 0.4% and 0.1% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Amarin (AMRN), which increased 4.1% and 2.7% respectively. They were followed by pharmaceutical company pharmaceutical company Silence Therapeutics (SLN) and ming company BHP (BHP), which advanced 1.5% and 1.3% respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), shed 18% and 3.4% respectively. They were followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and financial services company HSBC (HSBC), which lost 2.7% and 1.8% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.